Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) insider Arnnon Geshuri sold 7,500 shares of Teladoc Health stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $15.06, for a total value of $112,950.00. Following the sale, the insider now owns 38,470 shares of the company’s stock, valued at approximately $579,358.20. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Teladoc Health Stock Up 1.5 %
Shares of Teladoc Health stock opened at $15.27 on Thursday. The stock has a 50-day moving average price of $17.60 and a 200 day moving average price of $18.60. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47. Teladoc Health, Inc. has a 1 year low of $14.29 and a 1 year high of $30.41.
Teladoc Health (NYSE:TDOC – Get Free Report) last announced its quarterly earnings data on Tuesday, February 20th. The health services provider reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.05. The firm had revenue of $660.50 million during the quarter, compared to the consensus estimate of $670.79 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.23) EPS. On average, research analysts expect that Teladoc Health, Inc. will post -1.07 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of analysts recently commented on the company. Royal Bank of Canada dropped their price objective on Teladoc Health from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, February 21st. Citigroup lowered their price target on Teladoc Health from $21.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, February 21st. Cantor Fitzgerald started coverage on Teladoc Health in a report on Thursday, February 29th. They issued an “overweight” rating and a $22.00 price target for the company. Piper Sandler lowered their price target on Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, February 21st. Finally, Barclays decreased their target price on Teladoc Health from $26.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, February 21st. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Teladoc Health currently has an average rating of “Hold” and a consensus price target of $22.43.
View Our Latest Stock Analysis on Teladoc Health
Teladoc Health Company Profile
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Further Reading
- Five stocks we like better than Teladoc Health
- Investing in Travel Stocks Benefits
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Insider Buying Explained: What Investors Need to Know
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Canadian Penny Stocks: Can They Make You Rich?
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.